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Abstract
The association of MMP-2 (matrix metalloproteinase 2, 72-kD collagenase
IV) with invasive and metastatic capacity of tumor cells has implicated a
potential role in the prognosis for cancer patients. However, no larger study
has been done to prove this hypothesis. The present study was therefore
designed to investigate the prognostic impact of MMP-2 in a prospective
series of 203 gastric cancer patients. MMP-2 expression was measured immu-
nohistochemically and scored semiquantitatively (score 0–3) in carcinoma
cells, and results were correlated with clinicopathological tumor parameters
and parameters of the urokinase-type plasminogen activator (uPA) system.
Survival analyses were done using the Kaplan-Meier method (log-rank statis-
tics) and multivariate Cox analysis. Significant correlations were found for
MMP-2 and Laurén’s classification, M stage and proteases/inhibitors of the
uPA system in the primary tumor. Kaplan-Meier analysis revealed an associa-
tion of increasing MMP-2 expression with worse prognosis. This was especial-
ly seen in patients with a parallel high expression of uPA receptor. However,
differences in survival probabilities between low and high MMP-2 levels were
not significant. In a separate analysis of diffuse-type cancers, MMP-2 was sig-
nificantly associated with disease-free (p = 0.0056) and overall survival (p =
0.0426). Multivariately, MMP-2 was not an independent parameter. Our
results demonstrate that there is an association of immunohistochemical
detection of MMP-2 with prognosis of cancer patients. For diffuse gastric can-
cers, it is a significant prognostic parameter, however, not of independent
impact. The study further suggests that consideration of interrelated tumor-
associated proteases like uPA receptor in combination with MMP-2 may
improve its prognostic power.
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Introduction
Tumor cell invasion and metastasis is biologically
coherent with proteolytic destruction of surrounding ma-
trix, which evidently seems to be achieved by a series of
tumor-associated serine, aspartic, cysteine, threonine and
metalloproteinases [1–3]. One decisive step in metastasis
is lysis of collagen IV [4], a basic element of constitutive
basement membranes of blood vessels, to enable invasion
of tumor cells into the systemic circulation. MMP-2 (72-
kD collagenase type IV), a member of the zink-dependent
matrix metalloproteinases (MMPs), is an enzyme which is
able to degrade collagen IV as well as collagen type V,
gelatins, laminin and fibronectin [5] and thus is more and
more discussed as being an essential tool of metastasizing
tumor cells. As other MMPs, MMP-2 is secreted as an
inactive proenzyme and activated by N-terminal proteo-
lytic cleavage [5, 6]. As potential activators, other tumor-
associated proteases such as urokinase-type plasminogen
activator (uPA) [7, 8] and a recently identified mem-
brane-associated metalloproteinase (MT-MMP) are dis-
cussed [9]; however, mechanisms and involved factors of
activation remain to be elucidated. In addition, the activi-
ty of MMP-2 seems to be modulated by tissue inhibitors
of metalloproteinases (TIMPs) and especially TIMP-2 [5,
10, 11]. Besides an inhibiting effect, complexing with
TIMP-2 at C-terminal pro-MMP-2 diminishes the proteo-
lytic activity of MMP-2 but prolongs its half-life and local-
izes it to a specific cellular binding site [11]. This is com-
parable to the interaction of uPA and plasminogen activa-
tor inhibitor type 1 (PAI-1) at the uPA receptor (uPA-R)
which has already been shown for the uPA system [12],
where a similar complexing of uPA, PAI-1 and uPA-R
leads to a concentration of the proteolytic effect and
dynamic recycling of the protagonists [12].
In human cancers, expression of MMP-2 has been
localized to stromal cells but also tumor cells on the DNA,
mRNA and protein level [13–19]. In breast cancer, activi-
ty of MMP-2 was significantly associated with malignan-
cy [20], and elevated MMP-2/TIMP-2 levels measured by
RT-PCR correlated with lymph node involvement [19].
For gastric cancer, MMP-2 was even postulated as a char-
acteristic of the malignant phenotype in contrast to
MMP-9, the 92-kD form of collagenase IV [21], which can
be activated by MMP-2 [22]. MMP-2 has been detected
preferentially on advanced gastric carcinoma cells by
immunohistochemistry and was correlated with vascular
invasion [15]. Higher percentages of MMP-2-positive tu-
mor cells studied immunohistochemically had been
found in patients who died from primary gastric cancer
[23]. Thus, an association of MMP-2 with poor prognosis
of cancer patients has been suggested [17, 23]. However, a
large clinical study on a potential prognostic impact of
MMP-2 in human cancer to test this hypothesis has not
been performed to date.
Therefore, the present study was designed to examine
the role of MMP-2 evaluation in the prognostic analysis of
cancer. In a large prospective series of 203 patients with
gastric cancer, MMP-2 was investigated immunohisto-
chemically in tumor cells. As potential interactions or
activation mechanisms have been speculated for the uPA
system [7, 8], respectively, coexpression of parameters of
this system (uPA, uPA-R, PAI-1 and PAI-2) [24] was also
considered in our analysis.
Patients and Methods
Patients
A consecutive prospective series of 247 patients was operated on
for primary gastric cancer between February 1989 and October 1991;
203 of them were tumor resected. The mean age was 63.8 years (SD
10.4, range 22–87), the male/female ratio was 1.14 (108/95). Of 203
patients, 70% (143) could be resected curatively with radical lymph
node dissection including compartments I and II. Of the remaining
30% with palliative resection, 22 revealed microscopic, 38 macro-
scopic tumor residues.
TNM classification of resected tumors revealed 14.8% UICC
stage Ia, 12.8% stage Ib, 14.3% stage II, 19.2% stage IIIa, 13.8% stage
IIIb and 25.1% stage IV. According to Laurén’s classification, 108
tumors (53.2%) were intestinal, 86 (42.4%) diffuse and 9 (4.4%)
mixed-type carcinomas.
Twelve patients were given intraoperative radiation therapy (all
curatively resected, 28 Gy). Neoadjuvant chemotherapy was applied
to 3, adjuvant chemotherapy to 11 patients. Five patients received
chemotherapy after noncurative resection.
Follow-up was done prospectively 6, 12, 18, 24 months after
operation and at 1-year intervals thereafter. It consisted of physical
examination, abdominal ultrasound, gastroscopy, chest X-ray, hema-
tology and blood chemistry and screening for the tumor markers
CEA, Ca 19–9 and Ca 72–4. In case of suspicion of recurrence, con-
firmation by biopsy or second-look operation was recommended. If
this could not be achieved, imaging procedures were accepted for
diagnosis of recurrence. Causes of death were diagnosed clinically.
Immunohistochemical Staining
For immunohistochemistry, tumors were formalin-fixed and par-
affin-embedded immediately, cut into 4-Ìm serial sections, deparaf-
finized and inactivated for endogenous peroxidase (0.5% hydrogen
peroxide, 20 min). Then slides were rehydrated.
Staining was performed at room temperature and each incuba-
tion step was followed by thorough washing in 0.001% Brij/PBS (Sig-
ma, Deissenhofen, Germany). Slides were preincubated with 5%
horse serum/PBS for 20 min. Monoclonal antibody No. 14-4012-
10004 (Paesel-Lorei, Frankfurt/Main, Germany, IgG1) against
72kD-collagenase (MMP-2) was incubated for 60 min (1.5 Ìg/ml).
Staining was continued using a highly sensitive avidin-biotin elite kit
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Fig. 1. Immunohistochemical staining
for MMP-2 in a gastric carcinoma of the
intestinal type (G2), score 2.
(Vectastain, Burlingame, Calif., USA). Slides were incubated with
horse-derived bridging antibody (7.5 Ìg/ml) for 30 min, followed by
Vectastain ABC elite complex for 30 min. After washing in PBS, ami-
noethylcarbazole (Sigma) was added for 15 min as enzyme substrate.
Finally, slides were counterstained with hematoxylin.
One section of each tumor treated with antibody MLG/7S (Nor-
dic, Tilburg, the Netherlands) against murine IgG instead of the pri-
mary antibody in equimolar protein concentration served as nega-
tive, a routinely processed tumor with known strong MMP-2 expres-
sion as positive control.
All slides were coded and evaluated without knowledge of patient
and clinical status by an experienced pathologist (R.B.). Scoring was
exclusively restricted to tumor cell staining, and stromal staining was
not considered. Staining results were classified semiquantitatively
into four groups according to the number of positively stained tumor
cells: score 0 = negative; score 1 = lower or equal to 30% positive
tumor cells; score 2 = 30–70% positive cells; score 3 = greater or equal
to 70% positive tumor cells.
For staining regarding uPA, uPA-R, PAI-1 and PAI-2, see the
methodology section in Heiss et al. [24].
Statistical Analysis
¯2 analysis was performed to determine correlations between
expected and detected frequencies. Parameters for ¯2 analysis were
considered as follows: MMP-2, uPA, uPA-R, PAI-1 and PAI-2 were
classified into semiquantitative groups (score 0–3), Laurén’s classifi-
cation as intestinal versus diffuse/mixed, lymphangiosis and vessel
infiltration as presence versus absence and pT, pN, M, UICC, G and
Borrmann as established. Kaplan-Meier analysis evaluated group-
oriented life-table curves and was confirmed by Mantel-Cox log-rank
statistics [25, 26]. The Cox proportional hazard model was per-
formed for multivariate analysis, considering established risk factors
in gastric cancer [27]. Parameters for multivariate analysis were con-
sidered as stated for ¯2 analysis; intended surgical curability (cura-
tive/not curative) and operative procedure (extended/not extended)
were dichotomized. All statistics were done two-sided at a signifi-
cance level of p = 0.05.
Results
Of 203 patients, 189 (139 curatively resected) could be
followed every 6 months postoperatively (14 died in hos-
pital); 3 patients were lost to follow-up. The median time
of follow-up was 31 months, the range 9–56. Ninety-three
patients died, 82 with malignant disease, but one not cau-
sative.
In curatively resected patients, 47 recurrences were
observed (10 as peritoneal carcinosis, 24 as locoregional
recurrence, 13 as distant metastasis, of which 7 liver,
2 bone, 1 brain and 1 generalized metastasis).
Immunohistochemical staining (example in fig. 1) was
also seen in surrounding fibroblasts and endothelia. How-
ever, stromal staining was not considered in scoring.
Correlation with Clinicopathological
Tumor Parameters
The intensity of MMP-2 staining in tumor epithelia
did neither correlate with pT (p = 0.6598), pN (p =
0.8420), UICC classification (p = 0.3282), grading (p =
0.4298), Borrmann classification (p = 0.2712) nor with
lymphangiosis carcinomatosa (p = 0.9566) or vessel infil-
tration (p = 0.1815). A significant correlation (table 1) was
seen, however, for M stage (p = 0.0212) and Laurén’s clas-
sification (p = 0.0115), where higher staining scores were
associated with diffuse types.
Correlations with Proteases/Inhibitors of the uPA
System
Expression of uPA system parameters had been inves-
tigated immunohistochemically; results have been shown
previously [24]. The intensity of uPA staining did posi-
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Fig. 2. Overall survival of 139 curatively resected gastric cancer
patients according to semiquantitative scoring (0–3) of immunohis-
tochemical MMP-2 detection in tumor cells (Kaplan-Meier analysis);
p (Mantel-Cox log-rank test) = 0.2743. Score 0: cases 22, events 8,
mean survival time (MST) 43.19 months, standard deviation (SD)
6.22; score 1: cases 44, events 11, MST 44.91 months, SD 5.60; score
2: cases 46, events 15, MST 41.65 months, SD 5.98; score 3: cases 27,
events 16, MST 31.58 months, SD 7.06.
Fig. 3. Overall survival of 139 curatively resected gastric cancer
patients according to dichotomization of immunohistochemical
MMP-2 detection in tumor cells between low (score 0/1) and high
(score 2/3) staining degrees (Kaplan-Meier analysis); p (Mantel-Cox
log-rank test) = 0.0709. Low MMP-2 levels: cases 66, events 19, mean
survival time (MST) 43.26 months, standard deviation (SD) 4.62;
high MMP-2 levels: cases 73, events 31, MST 36.62 months, SD
6.52.
tively correlate with MMP-2 detection (p = 0.0027).
There was also a significant positive association with
uPA-R (p = 0.0004), PAI-1 (p ! 0.0001) and PAI-2 (p =
0.0358; table 1).
Prognostic Analysis of MMP-2 Expression
Kaplan-Meier survival analysis of immunohistochemi-
cal MMP-2 detection did not show significant differences
in disease-free (p = 0.3903) and overall survival of cura-
tively resected cases (p = 0.2743, fig. 2) and all 189
patients (p = 0.4645). Also, dichotomization of MMP-2-
negative versus MMP-2-positive cases did not result in
significant prognostic differences (curatively resected pa-
tients/disease-free survival: p = 0.6257, overall survival:
p = 0.7578, all patients/overall survival: p = 0.5789).
However, dichotomization between low (score 0/1)
and high MMP-2 expression (score 2/3) showed a correla-
tion of high MMP-2 levels with worse outcome (overall
survival, curatively resected patients: p = 0.0709, fig. 3, all
patients: p = 0.1105; disease-free survival: p = 0.4188). As
univariate prognostic significance could not be shown for
MMP-2, multivariate Cox regression analysis considering
established risk factors in gastric cancers was not per-
formed.
Table 1. Overview of significant ¯ 2 correlations of MMP-2
Significantly
correlating variable
p value
M 0.0212
Laurén 0.0115 (high scores in diffuse types)
uPA 0.0027
uPA-R 0.0004
PAI-1 !0.0001
PAI-2 0.0358
MMP-2 and uPA system parameters are classified semiquantita-
tively (score 0–3), Laurén’s classification and M stage were entered as
dichotomized variables (diffuse/mixed vs. intestinal, M0 vs. M1).
Prognostic Analysis of MMP-2 according to Laurén’s
Classification
As higher immunohistochemical MMP-2 scores were
significantly correlated with Laurén’s diffuse/mixed types
in ¯2 analysis, Kaplan-Meier survival calculations were
performed for intestinal and diffuse/mixed carcinomas
separately.
Disease-free survival
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Fig. 4. Overall survival of 54 curatively resected patients with
diffuse/mixed gastric cancers according to dichotomization of immu-
nohistochemical MMP-2 detection in tumor cells between low (score
0/1) and high (score 2/3) staining degrees (Kaplan-Meier analysis);
p (Mantel-Cox log-rank test) = 0.0056. Low MMP-2 levels: cases 34,
events 9, mean survival time (MST) 47.73 months, standard devia-
tion (SD) 4.28; high MMP-2 levels: cases 20, events 13, MST 28.50
months, SD 7.50.
Fig. 5. Overall survival of 33 curatively resected gastric cancer
patients with high (score 3) tumor cell evidence of uPA-R according
to immunohistochemically detected MMP-2 presence or absence
(Kaplan-Meier analysis); p (Mantel-Cox log-rank test) = 0.2598.
MMP-2 negative: cases 5, events 2, mean survival time (MST) 47.50
months, standard deviation (SD) 6.50; MMP-2 positive: cases 28,
events 13, MST 33.41 months, SD 6.96. In comparison, survival
curves for patients with low expression of uPA-R (score 0–2) are indi-
cated by dashed lines, again for MMP-2 presence versus absence;
p (Mantel-Cox) = 0.7111. MMP-2 negative: cases 17, events 6, MST
45.00 months, SD 6.00; MMP-2 positive: cases 89, events 13, MST
48.00 months, SD 3.00.Table 2. Association of immunohistochemical MMP-2 detection
in 89 diffuse/mixed gastric cancers (54 curatively resected) with
prognosis according to Mantel-Cox log-rank test
p (Mantel-Cox) for
semiquantitative
scores 0–3
p (Mantel-Cox) for
dichotomization
0/1 and 2/3
(curatively resected patients)
0.2318 0.0426
Overall survival
(curatively resected patients)
0.0448 0.0056
Overall survival
(all patients)
0.1884 0.1092
Analysis for semiquantitative scores 0–3 and dichotomization
between scores 0/1 and 2/3.
For intestinal types (n = 100), no significant associa-
tion with prognosis was seen (curatively resected patients:
disease-free survival p = 0.6749, overall survival p =
0.8960; all patients: overall survival p = 0.9665).
In diffuse/mixed types (n = 89), however, a significant
association with overall survival was revealed for cura-
tively resected patients (p = 0.0448, table 2). With dicho-
tomization between low (score 0/1) and high (score 2/3)
MMP-2 detection (table 2), a significant association with
prognosis was seen. As an example, Kaplan-Meier analy-
sis for overall survival of curatively resected patients is
given in figure 4 (p = 0.0056).
Multivariate analysis performed to correct these re-
sults for established risk factors in gastric cancer (pT, pN,
M, G, intended surgical curability, tumor localization and
diameter, extended vs. not extended operative procedure)
and for uPA system parameters did not establish MMP-2
as a new independent prognostic parameter for diffuse
gastric cancers (table 3). As the stepwise Hazard model
revealed, the univariate impact of MMP-2 was lowered by
the strong correlation with PAI-1, uPA and uPA-R (ta-
ble 1) as confounding variables.
Prognostic Impact of MMP-2 Considering Expression
of uPA System Parameters
In view of biological interactions between different
tumor-associated protease systems, we asked whether ex-
pression of MMP-2 would be modified in prognostic
impact when patients with strong evidence of uPA system
parameters [24] were separately analyzed.
Surgical
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Table 3. Multivariate analysis of MMP-2 in diffuse/mixed gastric cancers
Variable Disease-free survival, curatively
resected patients (n = 54)
p value odds ratio
(relative risk)
95% CI
Overall survival, curatively
resected patients (n = 54)
p value odds ratio
(relative risk)
95% CI
Overall survival,
all patients (n = 89)
p value odds ratio
(relative risk)
95% CI
curability – – – – – – !0.001 6.87 3.11–15.20
pT 0.041 5.22 1.93–14.11 0.043 2.65 1.65–4.26 n.s. – –
Tumor
diameter n.s. – – n.s. – – 0.038 1.80 1.49–2.18
uPA !0.001 2.05 1.50–2.79 !0.001 2.42 1.64–3.58 0.002 2.05 1.68–2.48
uPA-R n.s. – – n.s. – – 0.026 1.80 1.56–2.07
PAI-1 0.020 2.78 1.80–4.32 n.s. – – n.s. – –
MMP-2 n.s. – – n.s. – – n.s. – –
Multivariate analysis of immunohistochemical MMP-2 detection in 89 diffuse/mixed type gastric cancers considering additional risk
factors in gastric cancer (pT, pN, M, G, lymphangiosis carcinomatosa, vessel infiltration, surgical curability, extended/not extended resection,
tumor localization and diameter, Borrmann, uPA, PAI-1). Parameters were analyzed as stated in the Methods. MMP-2 was dichotomized
(score 0/1 vs. 2/3). Level of significance, relative risk estimated by odds ratio and 95% confidence interval (CI) are given in the table for those
parameters that were revealed to be independent risk factors (significant p value, relative risk 11). n.s. = Not significant.
In the subgroup of patients with high expression of
uPA-R (score 3, 33 curatively resected patients), Kaplan-
Meier analysis showed an evident, however not signifi-
cant association of MMP-2 presence (vs. absence) with
poor prognosis (fig. 5; survival curves given in compari-
son to low uPA-R expression). This was not seen in sub-
groups of cases with score 3 detection of uPA, PAI-1 or
PAI-2.
In patients with low expression of uPA, uPA-R (fig. 5),
PAI-1 or PAI-2 (scores 0, 1), there was no association of
MMP-2 detection with prognosis.
Discussion
This is the first study which investigated the prognostic
relevance of MMP-2 in a large prospective series of cancer
patients. It revealed a positive association of high MMP-2
levels detected immunohistochemically with a poorer
outcome of gastric cancer patients, however not as a sig-
nificant clinical prognostic parameter. In contrast, for dif-
fuse cancer types MMP-2 is a significant, but not indepen-
dent indicator of prognosis. Further consideration of the
uPA system as an interactive pattern of proteases for the
first time revealed that potentially a more detailed biolog-
ical prediction of prognosis will be possible if a combina-
tion of proteases is considered.
A significant association of MMP-2 with prognosis
could be shown for diffuse gastric cancers. In multivariate
analysis this impact was lowered by the strong correlation
with uPA, uPA-R and especially PAI-1, a dominant prog-
nostic parameter in gastric cancer [24]. In contrast to oth-
er authors [15, 16], we saw a significant correlation of
MMP-2 immunostaining with Laurén’s classification,
higher staining scores being seen in diffuse types, a find-
ing which is corroborated by observations of Grigioni et
al. [23]. The discrepancy to David et al. [16] and Nomura
et al. [14, 15] can be explained by a higher number of
cases investigated (189 in contrast to 87 and 46, respec-
tively). However, diffuse gastric cancers are characterized
by spread of cancer cell nests or tumor cells surrounded by
extensive stroma [28], and probably MMP-2 is of more
biological relevance for cancers with those morphological
characteristics. Correspondingly, Höyhtyä et al. [18] re-
ported stronger MMP-2 staining at the periphery of tumor
cell nests in gastric, breast and endometrial, ovarian and
prostate cancers. For human pancreatic cancer, Gress et
al. [13] demonstrated a concentration of MMP-2 levels in
tumor areas with strong desmoplastic reactions. These
observations agree with our results and support the hy-
pothesis that relevance of MMP-2 may be special for
tumors with the morphological features of a low tumor
cell/stroma ratio, diffuse tumor cell nests and strong stro-
mal reaction.
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The lack of overall prognostic significance seems to be
astonishing since collagenase IV as one key enzyme for
destruction of basement membranes should be essential
for aggressiveness of tumors and thus risk of relapse and
metastasis [4]. Moreover, the 72-kD form of collagenase
IV as an activator of the 92-kD form of collagenase IV
(MMP-9) [22] has been defined as one characteristic of
malignant gastric cancer cells [21], and Nomura et al. [15]
demonstrated significant correlations of immunohisto-
chemical MMP-2 evidence with advanced gastric cancer
stages as well as vascular invasion. This corresponds to
the significant association with M stage in our series.
The failure of immunohistochemical MMP-2 analysis
to be of significant prognostic impact could have two
main reasons. First, immunohistochemistry does not dis-
tinguish between activated and latent MMP-2. As Nomu-
ra’s study indicates, not sole detection, but moreover evi-
dence of activation of MMP-2 in cancers may be decisive
[15]. Gelatin zymography revealed that the ratio of active
to total MMP-2 was significantly higher in carcinomas
than in normal tissue and significantly higher in advanced
than in early gastric cancer stages. Another study of the
same group indicates an important role of MT-MMP (a
metalloproteinase with a transmembrane domain [9]) in
combination with MMP-2 analysis. MT-MMP is thought
to be a surface-bound activator of MMP-2 in invasive
tumor cells [9, 14], and immunohistochemically detected
MT-MMP increases with grade of vascular tumor cell
invasion in gastric cancer [14]. Tumors with colocaliza-
tion of MT-MMP and MMP-2 significantly show higher
degrees of vessel infiltration, and gelatin zymography
demonstrated that active MMP-2 can only be detected in
tumor samples with positive evidence for MT-MMP [14].
These results indicate that biological and prognostic rele-
vance of MMP-2 may be a matter not of expression, but of
enzyme activity.
Furthermore, not immunohistochemical analysis of
MMP-2 alone, but evaluation of interacting factors could
be of prognostic importance. The activating role of MT-
MMP has already been discussed. Other authors postulate
that not MMP-2 expression alone, but more the balance
between MMP-2 and its specific inhibitor TIMP-2 [10]
may be decisive for prognosis. In RT-in situ-PCR analy-
ses of 23 cases of cervical carcinoma, Nuovo et al. [17]
demonstrated a ratio of MMP-2/TIMP-2 of approximate-
ly 1 as correlated with good prognosis, whereas increasing
ratios favoring MMP-2 were seen in cases with poor out-
come. In these cases, preferentially downregulation of
TIMP-2, not upregulation of MMP-2 was seen. In paral-
lel, Grigioni et al. [23] observed a higher MMP-2/TIMP-2
ratio in advanced gastric cancers. The balance between
the protease and its inhibitor may thus be essential for the
event that a tumor cell does metastasize. However, TIMP-
2 should not only be seen as an inhibitor of MMP-2.
TIMP-2 is able to form complexes with MMP-2 that
potentially protect MMP-2 from degradation and enable
binding to a membrane-bound MMP receptor, evidence
of which has been given by Emonard et al. [29]. Charac-
teristics and cycling of this receptor remain to be eluci-
dated; however, it has been speculated that, similar to the
uPA/PAI-1 complex, binding and recycling of MMP-2/
TIMP-2 may play a role in tumor growth and neoangio-
genesis [11, 12]. Correspondingly, TIMP-2 has been
shown as associated with poor prognosis in invasive blad-
der cancer [30].
Thus, in view of multiple interactions consideration of
additional factors of tumor-associated proteolysis has to
be postulated for further prognostic analyses of MMP-2.
As a first approach, this has been done in our present
study regarding the uPA system. The 55-kD serine pro-
tease uPA, its cellular receptor uPA-R and specific inhibi-
tors PAI-1 and PAI-2 have extensively been studied [8,
12, 31]; prognostic relevance of this system is established
[32, 33] and has been published by our group examining
the same series of gastric cancer patients [24]. As the uPA
system is discussed as being able to activate collagenases,
thus potentially MMP-2 [7, 8], we proposed that there
could be a correlation of expression and modification of
the prognostic impact of MMP-2 by this system. In fact,
¯2 analysis showed that uPA, uPA-R, PAI-1 and PAI-2 are
significantly positively correlated with MMP-2, which
potentially implies a corresponding regulation of those
enzymes. uPA, PAI-1 and PAI-2 failed to improve prog-
nostic relevance of MMP-2; however, in cases of high
expression of uPA-R, Kaplan-Meier analysis demon-
strated evident association of MMP-2 detection with
worse prognosis (see curves fig. 5), the low significance
level of which in our opinion should be explained by small
patient numbers. uPA-R as the membrane-bound center
of the uPA system is able to concentrate uPA activity by
focusing receptor-bound uPA [31]. Thus, the presence of
further enzymes in the proteolytic cascade like MMP-2
may become prognostically relevant as focused potential
of their activation is available. Finally, it should be
emphasized that immunocytochemical detection of
MMP-2 in tumor cells as performed in our study does not
necessarily imply that gastric tumor cells do secrete
MMP-2 themselves. As other immunohistochemical stud-
ies on MMP-2 in gastric cancers [14–16, 18], we corre-
spondingly saw MMP-2 staining also in fibroblasts and
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endothelia of the surrounding stroma (which was not con-
sidered in scoring). This also implies that cancer cells
could capture MMP-2 of surrounding stromal cells by a
surface-bound receptor or could even recruit stromal cells
for MMP-2 production as similarly postulated for uPA
and PAI-1 [19, 34–36]. This is supported by Nomura et al.
[15] who report staining of stromal cells in gastric carcino-
mas in contrast to normal gastric tissue, where stromal
cells stained only weakly or were negative for MMP-2. In
situ localization studies on DNA and mRNA levels as
done for other cancers like pancreatic or bladder cancer
[13, 17] are necessary to further investigate potential
tumor-stroma interactions.
In summary, our present study demonstrates that im-
munohistochemical detection of MMP-2 in gastric can-
cers does show a prognostic association especially in dif-
fuse gastric cancer; however, it is not an independent
prognostic parameter. Further investigations on the prog-
nostic value of MMP-2 should be done measuring acti-
vated MMP-2 and considering functionally related tu-
mor-associated proteases. As it is indicated by our analy-
sis of patients with additional high expression of uPA-R,
this concept could specify the very individual cancer
patient’s prognosis by means of biological parameter pat-
terns.
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V. Diehl (Guest Editor)
Bailliere’s Clinical Haematology
Int. Practice and Research – Hodgkin’s Disease
Bailliere Tindall, London 1966 GBP
640 pp; £30.−
ISBN 0–7020–2174–1
Hodgkin’s disease is a fascinating malignancy that seems to have
a distant pathology, epidemiology and therapy. Despite the many
uncertainties as to its etiology, much has been learned about its eval-
uation and treatment so that most patients with this disease can be
cured. Dr. Diehl has put together an extensive analysis of the disease
in a relative small book on its epidemiology, pathology, immunology,
diagnostic evaluation, treatment and outcomes. The eleven chapters
are very detailed expositions of the issues and are well referenced.
The material is helpful to the clinical oncologist since it compiles
information that may not be readily available in the clinical litera-
ture. The chapters on the molecular pathology and immunology are
excellent examples of new information – detailed and well summa-
rized.
There are a few disappointments in the organization of the book.
The excellent chapter providing a historical perspective by Dr.
Tubiana is put in the middle of the book. A deficiency that was some-
what disappointing was the organization of the chapters on treat-
ment. They are broken up into several chapters including the man-
agement of early, intermediate, late and relapsed patients. It is hard
to grasp an overall sense of what the recommendations for manage-
ment might be. The role of laparotomy on staging was not clearly
defined. It was like looking at a painting of pieces of the picture rath-
er than the whole scene. Dr. Tubiana would have been able to present
a more cohesive assessment because of her experience.
However, this book is a valuable addition to the library of an
academic oncologist as well as those individuals who see many
patients. For the investigator in the field, it also serves as a recent
overall update of the issues.
Paul P. Carbone, Madison, Wisc.
